Clinical Trials and Statistics Unit, Institute of Cancer Research, London, United Kingdom.
Centre for Trials Research, Cardiff University, Cardiff, United Kingdom.
JCO Precis Oncol. 2024 Jan;8:e2300441. doi: 10.1200/PO.23.00441.
The way late-onset toxicities are managed can affect trial outcomes and participant safety. Specifically, participants often might not have completed their entire follow-up period to observe any toxicities before new participants would be recruited. We conducted a methodological review of published early-phase dose-finding clinical trials that used designs accounting for partial and complete toxicity information, aiming to understand (1) how such designs were implemented and reported and (2) if sufficient information was provided to enable the replicability of trial results.
Until March 26, 2023, we identified 141 trials using the rolling 6 design, the time-to-event continuous reassessment method (TITE-CRM), the TITE-CRM with cycle information, the TITE Bayesian optimal interval design, the TITE cumulative cohort design, and the rapid enrollment design. Clinical settings, design parameters, practical considerations, and dose-limiting toxicity (DLT) information were extracted from these published trials.
The TITE-CRM (61, 43.3%) and the rolling 6 design (76, 53.9%) were most frequently implemented in practice. Trials using the TITE-CRM had longer DLT assessment windows beyond the first cycle compared with the rolling 6 design (52.5% 6.6%). Most trials implementing the TITE-CRM (91.8%, 56 of 61) failed to describe essential parameters in the protocols or the study result papers. Only five TITE-CRM trials (8.2%, 5 of 61) reported sufficient information to enable replication of the final analysis.
When compared with trials using the rolling 6 design, those implementing the TITE-CRM design exhibited notable deficiencies in reporting essential details necessary for reproducibility. Inadequate reporting quality of advanced model-based trial designs hinders their credibility. We provide recommendations that can improve transparency, reproducibility, and accurate interpretation of the results for such designs.
晚期毒性的处理方式会影响试验结果和参与者的安全性。具体而言,在招募新的参与者之前,参与者通常可能无法完成整个随访期以观察任何毒性。我们对使用部分和完全毒性信息设计的已发表早期剂量发现临床试验进行了方法学审查,旨在了解:(1)这些设计是如何实施和报告的;(2)是否提供了足够的信息以实现试验结果的可重复性。
截至 2023 年 3 月 26 日,我们使用滚动 6 设计、事件时间连续评估方法(TITE-CRM)、具有周期信息的 TITE-CRM、TITE 贝叶斯最优区间设计、TITE 累积队列设计和快速入组设计,共确定了 141 项试验。从这些已发表的试验中提取了临床环境、设计参数、实际考虑因素和剂量限制毒性(DLT)信息。
TITE-CRM(61 项,43.3%)和滚动 6 设计(76 项,53.9%)在实践中最常实施。与滚动 6 设计相比,使用 TITE-CRM 的试验在第一个周期之外的 DLT 评估窗口更长(52.5%比 6.6%)。实施 TITE-CRM 的大多数试验(91.8%,56/61)未能在方案或研究结果论文中描述基本参数。只有 5 项 TITE-CRM 试验(8.2%,5/61)报告了足以支持最终分析复制的信息。
与使用滚动 6 设计的试验相比,实施 TITE-CRM 设计的试验在报告复制所需的基本细节方面存在明显不足。高级基于模型的试验设计报告质量不足,阻碍了其可信度。我们提供了一些建议,可以提高此类设计的透明度、可重复性和对结果的准确解释。